BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$80.69 USD
-0.16 (-0.20%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $80.80 +0.11 (0.14%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Brokerage Reports
0 items in cart
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 761 - 780 ( 814 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Pediatric Phase 2 GALNS Trial Supplements Ongoing Phase 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals: December 2011 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Long-Term Growth Strengthened With Approval of Manufacturing Plant Expansion In Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials: Transient Choppy Naglazyme Sales & High R&D Caused A Miss. Reiterating NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q3 Preview: We Believe Consensus Is Achievable. Reiterating NEUTRAL But Increasing Fair Value To $33 From $31 Due To Time Value.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of September 4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials Beat, Guidance Raised, Plus H2 Clinical Catalysts But It''s in the Stock.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L